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Objective: The main challenge of screening a healthy population with low-dose com-
puted tomography is to balance the excessive use of diagnostic procedures with the
risk of delayed cancer detection. We evaluated the pitfalls, difficulties, and sources
of mistakes in the management of lung nodules detected in volunteers in the Cosmos
single-center screening trial.
Methods: A total of 5201 asymptomatic high-risk volunteers underwent screening
with multidetector low-dose computed tomography. Nodules detected at baseline or
new nodules at annual screening received repeat low-dose computed tomography at
1 year if less than 5 mm, repeat low-dose computed tomography 3 to 6 months later
if between 5 and 8 mm, and fluorodeoxyglucose positron emission tomography if
more than 8 mm. Growing nodules at the annual screening received low-dose com-
puted tomography at 6 months and computed tomography-positron emission tomog-
raphy or surgical biopsy according to doubling time, type, and size.
Results: During the first year of screening, 106 patients underwent lung biopsy and 91
lung cancers were identified (70% were stage I). Diagnosis was delayed (false-
negative) in 6 patients (stage IIB in 1 patient, stage IIIA in 3 patients, and stage IV
in 2 patients), including 2 small cell cancers and 1 central lesion. Surgical biopsy
revealed benign disease (false-positives) in 15 cases (14%). Positron emission tomog-
raphy sensitivity was 88% for prevalent cancers and 70% for cancers diagnosed after
first annual screening. No needle biopsy procedures were performed in this cohort of
patients.
Conclusion: Low-dose computed tomography screening is effective for the early de-
tection of lung cancers, but nodule management remains a challenge. Computed to-
mography-positron emission tomography is useful at baseline, but its sensitivity
decreases significantly the subsequent year. Multidisciplinary management and expe-
rience are crucial for minimizing misdiagnoses.
L
ung cancer is the most common cause of cancer death in developed countries.1
Low survival for the disease is mainly due to advanced stage of disease at di-
agnosis.2 Screening with low-dose computed tomography (LD-CT) in high-
risk subjects detects stage 1 disease, when it is curable by surgery, in a high proportion
of cases, with 88% reported 10-year survival.3 LD-CT screening thus seems to be
a promising method for reducing lung cancer mortality. However, the technique
also identifies large numbers of indeterminate nodules, many of which are inflamma-
tory or otherwise benign,4 yet small malignant lesions can be misdiagnosed.5 The
management of patients with such nodules is a challenge for the clinicians concerned
with screening and nodule evaluation, and few studies have addressed the difficulties
involved.6,7
LD-CT screening should diagnose a high proportion of stage 1 disease amenable to
curative surgery with low morbidity and mortality, with low rates of overtreatment for
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CT-PET 5 computed tomography-positron emission
tomography
LD-CT 5 low-dose computed tomography
benign nodules to thereby optimize cost-effectiveness.8 To
achieve this, the initially adopted screening protocol must
be continuously examined and improved in the light of expe-
rience gained in the management of patients with nodules.
The aim of this study was to analyze the diagnostic difficul-
ties encountered during the first 2 years of our ongoing 5-year
Cosmos9 screening study for lung cancer using LD-CT and to
explore the utility of computer-aided detection (CAD) volu-
metry and positron emission tomography (PET) to improve
the diagnostic accuracy of the protocol.
Materials and Methods
Between October of 2004 and October of 2005, 5200 asymptomatic
high-risk (smoking history of$ 20 pack-years) individuals aged 50
years ormorewere enrolled in our 5-year single-center trial (Cosmos)
and underwent baselinemultidetector LD-CT screening for lung can-
cer. The subsequent year, 4815 individuals (93%) presented for the
first annual LD-CT. The screening protocol, enrollment criteria,
LD-CT settings, and diagnostic algorithm have been described.9,10
The study was approved by the ethics committee of our institute,
and patients were enrolled after signing the apposite consensus.
Briefly, patients with noncalcified nodules detected at baseline or
new nodules 5 mm or less detected at annual screening were sched-
uled for repeat CT 1 year later. Patients with nodules between 5.1
and 8 mmwere scheduled for repeat CT 3 to 6 months later. Patients
with nodules greater than 8.1 mm, or growing lesions less than 8mm
after repeat scan, were scheduled for CT-PET. Lesions suspicious
for malignancy (growing or CT-PET positive) were scheduled for
surgical biopsy and additional interventions. Further investigations
(repeat LD-CT 6 months later, CT-PET, or surgical biopsy) for pa-
tients with growing nodules at subsequent annual screening de-
pended on type (non-solid, solid, or partially solid), doubling
time, and size of nodules. In Table 1 we report the evolution of612 The Journal of Thoracic and Cardiovascular Surgery c Sepdiagnostic algorithm in relation to the time of observation for inde-
terminate nodules detected at baseline.
To assess the effectiveness of this protocol, we defined false-pos-
itives as benign nodules undergoing surgical biopsy and false-neg-
atives as prevalent nodules diagnosed as lung cancer stage greater
than 1 at the second annual screening. CT-PET sensitivity and spec-
ificity for baseline cancers or cancers detected after annual screening
were also compared.
LD-CT scans of patients with delayed diagnosis because of pro-
tocol failure (false-negatives) were retrospectively assessed using
CAD and volumetry system11 (available since December 1, 2006,
at the European Institute of Oncology [EIO], Milan). Doubling
times were determined automatically and compared with manual
calculations based on the maximum diameter of the nodules (mea-
sured with an electronic caliper).
The CT equipment was a High Speed Advantage (General Elec-
tric, Milwaukee, Wis) with multidetector (8 or 16-slice) LD-CT
scans obtained with settings at 140 kVp, 30 mA, 1.75:1 pitch ratio,
and 2.5-mm slice thickness. Native digital imaging and communica-
tion in medicine images were processed using the lung V-Care CAD
system (General Electric). The system automatically detects and
segments potential regions of interest, flagging them on the CT im-
age. Nodules not detected automatically were flagged manually.
Nodules were extracted automatically using a 3-dimensional tem-
plate method, and characteristics (volume and shape) were com-
pared in sequential scans.
Statistical Methods
The utility of CT-PET was assessed by determining the sensitivity,
specificity, and accuracy. Fisher’s exact test was used to compare
the sensitivity, specificity, and accuracy of CT-PET for baseline nod-
ules and prevalent/incident nodules undergoing CT-PET after the
first annual screening scan.We compared themanually and automat-
ically calculated values of the nodules’ doubling time by means of
a scatter plot and correlation coefficient. Doubling times for stage I
versus stage II to IV cancers were compared using nonparametric
test for median. Survival was represented by the Kaplan–Meier
method: 95% confidence intervals were calculated.
Results
To February of 2007, when almost all compliant volunteers
had completed the baseline and first annual screening, the
rate of patients with at least 1 noncalcified nodule was 43%TABLE 1. Clinical characteristics of 7 patients with delayed lung cancer diagnosis
Patient
Size baseline
(mm)
Size 3
mo (mm)
Size 12
mo (mm)
Doubling
time (d) SUV 1 y SUV 2 y Treatment Tumor type Stage Status
1a 20.9 20.9 26.8 341 1.6 2.2–4.42 CT ADC IV AWD
2 4.0 Not done 16.0 NA NA NA CT SCLC IV AWD
3 3.7 Not done 13.3 65.4 NA 7.51 CT SCLC IV DOD
4 7.4 7.4 10 284.7 NA 6.21 CT-S ADC IIIA AWD
5 8 8 10 372.8 NA 5.42 S-CT ADC IIB NED
6 5.5 6.6 20 66.9 1.7 3.18 CT-RT SCC IIIA NED
7 4.2 Not done 10.9 89.2 NA 3.71 CT-S SCC IIIA NED
AWD, Alive with disease; NED, not evidence of disease; DOD, death of disease; CT, chemotherapy; RT, radiotherapy; S, surgery; ADC, adenocarcinoma; SCC,
squamous cell carcinoma; NA, not available. aThis patient refused further work-up and treatment after detection of this prevalent nodule.tember 2008
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been performed. Fifteen were benign lesions (14.4%), and 91
were lung cancers; 64 (70%) of these cases were stage I dis-
ease. Radical surgery was achieved in 79 patients (89%), and
24-month survival was 85% (95% confidence interval, 75–
94) (Figure 1).
Delayed Diagnosis
In 7 patients with a baseline nodule, lung cancer progressed
beyond stage I during the subsequent year (false-negative),
Figure 1. Overall survival in 89 screening-detected lung cancers.
CI, Confidence interval.in 6 cases because of diagnostic limit of the protocol (false-
negative cases) and in 1 case because the patient refused
treatment (Table 1). Figure 2 shows false-negative CT im-
ages obtained during the baseline and first annual screening.
Three patients had a baseline nodule 5 mm or less that had
progressed at the subsequent scan (scheduled, according to
the protocol, for 1 year later). In 2 cases, progression was
to stage IV (both small cell lung cancers; 1 patient is dead
of disease and the other is alive with disease under chemo-
therapy); in 1 case, the progression was to stage IIIA
(non–small cell, with 1 mediastinal node involved; radical
multimodality treatment was applied).
Baseline lesions between 5 and 8 mm progressed during
the subsequent year in 3 patients. Two patients underwent
LD-CT 3 months after baseline, but the lesions were judged
stable and scheduled, according to the protocol, to 9 months
follow up, when the scheduled first annual screening scan
was performed. At this annual screening scan, a secondary
pleural lesion was evident in 1 case (T4N0M0, treated with
surgical biopsy and definitive chemotherapy), whereas 1
other case had peribronchial lymph node metastasis (stage
T2N1M0 treated with surgery and adjuvant chemotherapy).
The third patient, with a suspicious central lesion, underwent
repeat LD-CT at 3 and 6months, and thenCT-PETwith a neg-
ative result (standard uptake value 1.7). After a further 6
months (annual screening scan), the disease had progressed
to stage IIIA with a single mediastinal node station involved;
the patient was treated with chemotherapy and radiotherapy.
Among those with a baseline nodule greater than 8 mm,
only 1 progressed beyond stage I in the subsequent year:
The nodule was a PET-negative ground-glass opacity. The
patient refused the proposed treatment, and contralateralFigure 2. Two false-negatives arising
from the diagnostic protocol. A–D, LD-
CT images of a centrally located lesion
of the right lower lobe taken every 3
months. CT-PET after the second LD-CT
was negative (SUV < 2). The lesion
was diagnosed as cancer from the
fourth LD-CT scan. A and B, A 7-mm le-
sion of the right upper lobe that re-
mained stable in maximum diameter at
3 months follow-up LD-CTafter baseline
scan. Nine months after follow-up, the
screening scan shows a small increase
in diameter, indicating cancer. At sur-
gery, the lesion was T2N1 squamous
cell carcinoma.
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oped in the subsequent year.
Computer-aided Detection and Volumetry
We retrospectively assessed nodules using CAD and volu-
metry in 24 patients with a baseline nodule diagnosed as ma-
lignant at the next screening scan. Median manually
calculated doubling time was 202 days (range 65–7900
days), as represented in Figure 3. Doubling time could be
calculated automatically with the CAD system in only 13
cases. Comparison of manually and automatically calculated
doubling times showed a poor correlation (R2 5 0.0018).
Figure 3. Distribution of the volume doubling time of 24 lung can-
cers diagnosed as malignant after first annual screening but de-
tected at baseline. The extreme value of 7900 days represents
a patient with a tumor stable in size that showed increased den-
sity.614 The Journal of Thoracic and Cardiovascular Surgery c SepIn 1 of the 3 patients with a baseline nodule between 5 and
8 mm and progression beyond stage I, CAD demonstrated an
increase in volume between scans 3 months apart, in the year
before diagnosis (increase 559–662 mm3, doubling time 369
days). In the other 2 cases, automatic nodule segmentation
was impossible because of pleural adherence in 1 case and
central position adherent to bronchial and vascular structures
in 1 case.
Doubling times, calculated at 1 year, of the 6 prevalent
nodules that progressed beyond stage I were not significantly
greater than those of prevalent nodules diagnosed as stage I at
the next screening scan (187 vs 202 days; P 5 .90).
Sensitivity and Specificity of Computed Tomography-
Positron Emission Tomography
Seventeen of the 91 CT-PET scans performed in patients with
lungmalignancies were false-negative. Overall CT-PET sensi-
tivitywas 81%.Specificity andpositive andnegativepredictive
values were 93%, 89%, and 94%, respectively; there were 15
false-positive nodules (Table 2). Sensitivity was 88% for prev-
alent nodules and 70% for cancers detected after annual screen-
ing (Table 3). For cancers detected at the annual screening,
CT-PET sensitivity tends to be lower (80% vs 65%) in preva-
lent nodules (nodules present at baseline) than in cancers
detected ‘‘de novo’’ (nodules not present at baseline)
(Table 4). For CT-PET–negative cancers, the median nodule
size was 8.7 mm compared with 13 mm for CT-PET–positive
cancers. The median doubling time was 233 days in PET-neg-
ative cancers and 116 days in PET-positive cancers.
False-Positives
Benign lesions were diagnosed at surgery (false-positives) in
15 patients (14% of surgical cases). Pathologic findings were
chronic inflammation in 7 cases, hamartoma in 3 cases, lym-
phoid hyperplasia in 3 cases, and other findings in 2 cases.
CT-PET was positive in 8 of these cases (false-positives). Sur-
gical treatment was preferred in all growing lesions, even in
PET-negative cases. Table 2 shows the characteristics of
false-positive nodules. Surgery for benign disease occurred
more often at annual screening nodules (19% of surgically
treated cases) than baseline nodules (11% of surgically treated
cases). These nodules were frequently PET negative and
smaller in size than baseline nodules, andmore often had a his-
tologic diagnosis of chronic inflammation. Figure 4 shows
some growing false-positive lesions subject to surgical biopsy.
Discussion
The main obstacles to the large-scale dissemination of LD-
CT screening for persons at high risk of developing lung can-
cer are overdiagnosis4,12 and overuse of invasive procedures,
with increased screening costs and risks of morbidity for
those with benign disease. In addition, reduction of mortality
in a screened population has not been demonstrated,13 mainlytember 2008
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TSTABLE 2. Characteristics of false-positive lung nodules at years 1 and 2 of computed tomography screening and type of
surgery
Overall after baseline and
annual screening After baseline screening After annual screening
No. in relation to total surgical cases 15/104 7/62 8/42
No. in relation to total screened 15/5200 7/5200 8/4816 (0.17%)
subjects (0.29%) (0.13%)
CT-PET positive 8/15 5/7 3/8
Growing 7/15 1/7a 6/8
Mean size(mm) 16.5 20.3 (range 8–34) 13.1 (range 8.6–25)
Diagnoses
Hamartoma 3/15 2/7 1/8
Chronic inflammation 7/15 2/7 5/8
Lymphoid hyperplasia 3/15 2/7 1/8
Other 2/15 1/7 1/8
Wedge in VATS 5/15 1/7 4/8
Wedge in thoracotomy 9/15 6/6 3/8
Lobectomy 1/15 0/7 1/8
VATS, Videothoracoscopic approach; CT-PET, computed tomography-positron emission tomography. aGrowing at 3 months.because of the long follow-up required by the ongoing ran-
domized trial.14
Although overdiagnosis may be a feature of all screening
programs, clinical,15–17 biological,18,19 and molecular
data20,21 suggest that it is less important in lung cancer than
other cancers, although not all authors agree.13
In regard to the fear of invasiveness of the screening
process among patients with benign disease, we conceived
the present trial to use noninvasive procedures until rea-
sonable suspicion of cancer was obtained. Basically, this
meant using CT-PET for suspicious nodules (.8 mm, or
growing lesions # 8 mm after repeat scan), whereas
many other trials resort to fine-needle aspiration biopsy.6
We recently reported an assessment (American Society
of Clinical Oncology 2007) of the results obtained during
the first year (after baseline screening) of the study. We
TABLE 3. Sensitivity, specificity, and accuracy of computed
tomography-positron emission tomography: Overall results
compared with nodules detected at baseline screening and
computed tomography-positron emission tomography
outcome for nodules detected at annual screening
Overall
baseline
and annual
screening
During
baseline
screening
During
annual
screening
P value
baseline
vs annual
Sensitivity 81% 88% 70% .049
Specificity 93% 94% 87% .37
Accuracy 88% 92% 77% .007
Sensitivity and accuracy of CT-PET was significantly reduced for cancers
diagnosed at first annual screening compared with those diagnosed at
baseline screening.The Journal of Thofound that CT-PET had good sensitivity (88%) and speci-
ficity (94%) for these prevalent lesions, and only 14% of
screened subjects who underwent invasive diagnostic pro-
cedures had benign disease.9
The aim of the present study was to analyze in detail the
reasons for protocol failures in the first year of our single-
center lung cancer screening study. The present study shows
a small percentage of delayed cancer diagnoses. Most (50%)
delayed cancers arose from 5- to 8-mm nodules. Our protocol
scheduled these nodules to repeat LD-CT at 3 months. How-
ever, visual assessment of growth during this short period of
time failed to identify very small differences in size. Retro-
spective evaluation with CAD in these cases found doubling
times suspicious for cancer in approximately one third of 5-
to 8-mm nodules that progressed beyond stage I.
In addition, some nodules, particularly the non-solid type,
may present a stable size but increased density over time. For
this reason, we have introduced the variation of the density in
the diagnostic algorithm as a potential indication to surgical
biopsy.
TABLE 4. Computed tomography-positron emission
tomography outcomes for cancers diagnosed after annual
screening
Annual screening
incident nodules
Annual screening
prevalent nodules
P value incident
vs prevalent
Sensitivity 80% 65% .68
Specificity 88% 87% 1.00
Accuracy 83% 74% .78
CT-PETsensitivity tends to be lower (80% vs 65%) in prevalent cancers (nod-
ules present at baseline but diagnosed as cancer 1 year later) than in can-
cers detected ''de novo'' (nodules not present at baseline).racic and Cardiovascular Surgery c Volume 136, Number 3 615
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In both cases, a centrally located nod-
ule had increased in size and volume
compared with baseline (a) on repeat
scan (b); both were benign at surgical
biopsy. A, The lesion had a doubling
time of 162 days and negative PET
scan. Lobectomy was necessary for
removal. Histology showed chronic
inflammation. B, The lesion was re-
moved via a small lateral thoracotomy,
and pathologic examination docu-
mented a scissural lymph node.CAD is not part of the routine diagnostic approach be-
cause its use is not well established in EIO. In the future,
the routine application of this software method is likely to
improve accuracy for the measurement of such nodules,
and it is hoped that experience and technical improvements
will further increase the sensitivity and accuracy of the tech-
nique.
The present study indicates that CT-PET is significantly
less sensitive (70%) for cancers detected at annual screen-
ings, mainly because they are smaller and slower growing
than prevalent nodules. The threshold was based on maxi-
mum pixel-standardized uptake value. As previously re-
ported,9 the threshold was 2 at the beginning of the study,
but after 1 year we found that sensitivity was increased with-
out reducing specificity by using a lower maximum pixel-
standardized uptake value threshold to 1.5 in cases of nodules
less than 1 cm or non-solid nodules.
Another important finding of the present study was that
the number of false-positive cases at surgery was greater in616 The Journal of Thoracic and Cardiovascular Surgery c Sepnodules biopsied after the annual screening scan than in prev-
alent nodules biopsied at baseline scan, and pathologic find-
ings showed more chronically inflamed nodules after the
first annual screening scan. Most of these false-positives oc-
curred during the first half of the first annual screening; after
that, the introduction of more restrictive criteria for surgical
resection (additional LD-CT after antibiotics instead of pro-
ceeding directly to surgical biopsy in new suspicious lesions)
reduced the number of surgical false-positives. In regard to the
sensitivity of the ongoing protocol, it is possible that the false-
negative rate will increase over time. The evolution of diag-
nostic protocol algorithm for the management of pulomonary
nodules until the second year of screening trial is fully de-
scribed in Appendix 1.
Conclusions
Our CT screening protocol for lung cancer provides good
sensitivity and specificity, with only a small proportion of
screened subjects undergoing invasive diagnostic procedurestember 2008
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TSfor benign disease and a small number of cancers progressing
beyond stage I. Our data indicate that the introduction of CAD
and volumetry, reduction of CT-PET positivity thresholds,
and accumulation of experience by ourmultidisciplinary nod-
ule management team will further improve the diagnostic ac-
curacy of the protocol.
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creased maxSUV threshold for small and non-solid nod-
ules and the separation between solid or partially solid
nodules and non-solid nodules in terms of interval of fol-
low-up.Time 0 Nodules , 5 mm: LD-CT in 1 y
Nodules 5–8 mm: LD- CT at 3 mo
Nodules . 8 mm: CT-PET (maxSUV threshold 2)
12 mo Nodules , 5 mm: LD-CT in 1 y
Nodules 5–8 mm: LD-CT at 3 mo
Nodules . 8 mm: LD-CT at 1 mo after antibiotics, if stability or progression: CT-PET
Max SUV threshold . 2 for nodules . 1 cm and solid or partially solid
Max SUV threshold . 1.5 for nodules , 1 cm or non-solid lesions.
24 mo Solid or partially solid nodules
Nodules , 5 mm: LD-CT in 1 y
Nodules 5-8 mm: LD-CT at 3 mo
Nodules . 8 mm: LD-CT at 1 mo after antibiotics if stability or progression: CT-PET
Non-solid nodules
Nodules , 8 mm follow-up 1 y
Nodules . 8 mm: LD-CT at 3 mo with antibiotics, if increased in diameter or density biopsy, if stable LD-CT 1 y
Max SUV threshold . 2 for nodules . 1 cm and solid or partially solid
Max SUV threshold . 1.5 for nodules , 1 cm or non-solid lesions
LD-CT, Low-dose computed tomography; CT-PET, computed tomography-positron emission tomography; maxSUV, maximum pixel-standardized uptake value.racic and Cardiovascular Surgery c Volume 136, Number 3 617
